Preclinical Drug Discovery
The successful path from preclinical drug discovery to candidate selection is a complex, iterative process that requires an integrated, interdisciplinary approach. IITRI’s experienced team of toxicologists, analytical chemists, cancer biologists, infectious disease scientists, and molecular biologists partner with sponsors to develop the appropriate preclnical testing strategy to evaluate and advance lead drug candidates towards the clinic.
We offer a range of preclinical research services including efficacy studies of drug candidates, with in vitro assays and animal models available for cancer and infectious diseases. We also work with sponsors to explore the exposure and toxicology of lead candidates utilizing pharmacokinetic analysis and non-GLP exploratory toxicology testing for risk assessment of moving forward into GLP toxicology and safety programs.